Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 57,944,424
  • Shares Outstanding, K 213,620
  • Annual Sales, $ 11,449 M
  • Annual Income, $ 3,703 M
  • 36-Month Beta 0.83
  • Price/Sales 5.22
  • Price/Cash Flow 11.83
  • Price/Book 5.21

Price Performance

See More
Period Period Low Period High Performance
1-Month
244.28 +12.43%
on 05/31/17
284.46 -3.45%
on 06/23/17
+23.84 (+9.51%)
since 05/26/17
3-Month
244.28 +12.43%
on 05/31/17
291.90 -5.91%
on 04/25/17
+0.53 (+0.19%)
since 03/28/17
52-Week
213.70 +28.52%
on 06/29/16
307.33 -10.64%
on 08/02/16
+64.15 (+30.48%)
since 06/28/16

Most Recent Stories

More News
Better Days Ahead for the Pharma Sector?

Better Days Ahead for the Pharma Sector?

AZN : 34.35 (-0.64%)
JNJ : 133.82 (-0.88%)
LLY : 83.10 (+0.07%)
INCY : 134.33 (+3.08%)
NVS : 85.25 (-0.07%)
PFE : 33.75 (-0.06%)
BIIB : 274.64 (+1.25%)
Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs

Biogen (NASDAQ: BIIB) announced today the appointment of Catherine Steele as Senior Vice President of Corporate Affairs, effective July 17.

BIIB : 274.64 (+1.25%)
Biogen Inc Falls 1.16% on Heavy Volume: Watch For Potential Rebound

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $274.82 to a high of $279.40. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $277.58...

BIIB : 274.64 (+1.25%)
Watch for Biogen Inc to Potentially Rebound After Falling 1.16% Yesterday

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $274.82 to a high of $279.40. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $277.58...

BIIB : 274.64 (+1.25%)
Biogen's IMRALDI(R), an Adalimumab Biosimilar Candidate Referencing Humira(R), Granted Positive Opinion by Committee for Medicinal Products for Human Use

--Humira is the number-one prescribed biologic therapy in the world and accounts for almost half of anti-TNF healthcare expenditures in Europe

BIIB : 274.64 (+1.25%)
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt

Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.

CELG : 134.23 (+2.58%)
VRTX : 131.11 (+1.45%)
CLVS : 93.56 (+4.00%)
GILD : 71.92 (+1.80%)
SGEN : 54.72 (+6.48%)
REGN : 513.19 (+2.20%)
AMGN : 174.07 (+1.88%)
BIIB : 274.64 (+1.25%)
Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017

Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2017 financial results and a strategic update on Tuesday, July 25, 2017, before the financial markets open.

BIIB : 274.64 (+1.25%)
Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer

Biogen (NASDAQ: BIIB) announced today the appointment of Ginger Gregory, PhD, as Executive Vice President, Chief Human Resources Officer, effective July 17.

BIIB : 274.64 (+1.25%)
After Yesterday's Rally of 2.92% Shares Could Potentially Pullback

Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $252.94 to a high of $259.31. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of...

BIIB : 274.64 (+1.25%)
Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.

AZN : 34.35 (-0.64%)
AMGN : 174.07 (+1.88%)
BIIB : 274.64 (+1.25%)
NKTR : 19.51 (+3.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Support & Resistance

2nd Resistance Point 279.50
1st Resistance Point 277.07
Last Price 274.64
1st Support Level 270.65
2nd Support Level 266.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.